Anemia Clinical Trial
Official title:
Acceptability of Lipid-based Nutrient Supplements (LNS) for Women and Infants
Inadequate micronutrient intakes during pregnancy, lactation and infancy remain a major
problem in Ghana. Lipid-based nutrient supplements (LNS) made using vegetable oil, groundnut
paste, milk, sugar, and micronutrients may offer a solution.
The proposed study will test the acceptability of a lipid-based nutrient supplement designed
for infants (LNS-20gM) and another designed for pregnant and lactating women (LNS-P&L).
Participants will consume a test meal consisting of LNS-20gM (20 infants) or LNS-P&L (20
pregnant and lactating women) mixed with fermented maize porridge, after which they will be
given the respective LNS supplement for use at home for 14 d. Primary outcome is the
proportion of the test-meal consumed. The investigators hypothesize that subjects will
consume at 75% of the test meal offered.
This study is a taste test to confirm the acceptability of lipid-based nutrient supplements
(LNS), which are semi-solid pastes comprising groundnut paste, milk, sugar, vegetable oil
and micronutrients, for home fortification of foods consumed by infants and by pregnant and
lactating women. Two types of supplements will be evaluated, one for infants (LNS20gM) and
one for pregnant and lactating women (LNS P&L). The LNS-20gM is similar to the Nutributter
we used previously in Ghana and provides generally the Recommended Nutrient Intakes (RNI)
for 18 vitamins and minerals for infants from 6 to 18 mo of age. The LNS-P&L is modeled on
the UNICEF/WHO/UNU international multiple micronutrient preparation (UNIMMAP) for pregnant
and lactating women and similar products used in Guinea Bissau. Each supplement (20 g/day)
will provide 118 kcal/day.
Procedures:The study will be carried out in two phases. The first test trial will be
conducted within the premises of the Maternal and Child Health Clinics, where study
participants will be recruited.
Potential study participants or their mothers (in the case of infants) will be asked
verbally using a screening questionnaire at the time of recruitment if they are known to be
intolerant to peanut or milk products, in which case they will be excluded. Because infants
must have been receiving complementary foods at least 30 days prior to taking part in the
study, this will not be too difficult to find out. For subjects unaware of whether they are
intolerant to peanut or milk products, they will be asked not to go home immediately after
finishing the experiment, but to continue to remain in (or around) the testing room for at
least one hour whilst the study staff keep watch. Should there be any skin, respiratory or
gastrointestinal symptoms in any subject during that time, they will be immediately referred
to the hospital. When leaving the testing room for the home, those subjects (or their
mothers) will be given the project's mobile phone number to call in case there are any
symptoms during the next few hours.
Potential subjects or their mothers (in the case of infants) will be asked if they feel ill
using the screening questionnaire. Subjects who report any feeling of illness will be
excluded. The Maternal and Child Health clinics (MCH) where subjects will be recruited
provide mainly routine services for women (such as ante-natal services for pregnant women)
and children (such as weight monitoring and promotion and vaccination). We expect that
nearly all women and infants attending these clinics will be apparently in good health and
not ill.
Phase 1 - Test-feeding:
Study participants will be women (n = 20) ≥ 18 y of age who are either pregnant (n = 10) or
lactating (n = 10) and infants (n = 20 accompanied by their mothers) 6 - 12 mo of age
randomly-selected from Maternal and Child Health clinics in Manya and Yiko Krobo districts
of the Eastern Region of Ghana. All subjects must be apparently healthy and must not have
eaten any food (including breast milk) during the previous one hour.
1. Test-feeding of LNS P&L:
After consent, pregnant (n=10) and lactating women (n=10) will be asked to come to the
clinic the next day for an orientation session during which background data will be
collected and the experimental procedures will be practiced including tasting of the
food and completion of the tasting questionnaire. The second day will be Test Day 1,
during which the actual tasting will be recorded. Women will be asked to consume 45 g
of koko mixed with LNS P&L (prepared from mixing 150 g LNS-P&L with 600 g fresh koko
with moisture content of about 90%). Time taken to consume the entire amount, or
proportion of the amount consumed within 15 minutes, will be measured. Women will be
asked to rate the mixture's appearance, aroma, flavor, consistency and overall degree
of liking using a hedonic scale. On the third day (Test Day 2) of the trial, the above
procedures will be repeated using koko mixed with Nutributter instead.
Koko for the test feeding will be provided by the project. Project staff will purchase
fermented dough (the main ingredient) from the local market to prepare the koko under
good hygienic conditions in our project house. After preparation, the koko will be kept
hot in a thermos flask prior to being served to study participants at the MCH clinic.
Between the time the koko is prepared and the time the test feeding is completed, which
will take 2-3 hours, the koko can be kept at a temperature of 70 - 90 °C inside the
thermos flask to prevent bacterial contamination. The Nutributter and the LNS
supplements will be commercially produced by Nutriset SAS (Malaunay, France) and
provided to the Project for testing.
2. Test-feeding of LNS20gM:
After consent, the mother (or care-taker) of each participating infant will be asked to come
to the clinic with the child the next day for an orientation session during which background
data will be collected and the experimental procedures will be practiced including tasting
of the food and completion of the tasting questionnaire. The second day will be Test Day 1,
during which the actual tasting will be recorded. Mothers or caretakers will be given 50 g
of koko mixed with LNS 20gM (prepared from mixing 150 g LNS-20gM with 600 g fresh koko with
moisture content of about 90%). They will be asked to consume one teaspoon of the mixture (~
5 g), and then feed the rest (~ 45 g) to their infants after it is re-weighed. During this
time, the child should be awake and alert, and either calm or fussy - but not drowsy or
crying. Time taken by the child to consume the remaining portion, or proportion consumed by
the child within 15 minutes, will be measured. The mother or caretaker will then rate the
mixture's appearance, aroma, flavor and consistency based on her own opinion, and her
perception of the infant's degree of liking. Mothers will be asked to report to us if the
child vomits in the next hour, or develops any new symptoms such as rash or wheezing. On the
third day (Test Day 2) of the trial, the above procedures will be repeated using koko mixed
with Nutributter instead.
Phase 2 - Assessment under real-life conditions:
Pregnant and lactating women who participated in the Phase 1 trial will be given a two-week
supply of LNS P&L, which they will add to their prepared food daily during the two-week
period. Mothers of children who participated in the Phase 1 trial will receive LNS20gM,
which they will add to their infants' prepared food for 2 weeks. The dose for LNS P&L or
LNS20gM is 20 g/day. To ensure that subjects consume the entire daily dose, women will be
instructed, as done previously in our study in Ghana, to mix their own or their infant's
daily dose with 2-3 tablespoons of the food, to be consumed before consuming the rest of the
food.
Dosage and directions for use will be as follows: 20 g (~4 teaspoons) per day divided into 2
portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion
of the supplement to be consumed with 2-3 tablespoons of the already prepared food, and eat
the mixture before eating the rest of the food. Do not cook food with the supplement. Store
supplement at room temperature. There is no need for refrigeration.
A structured questionnaire will be used to gather background information on socioeconomic
status, and maternal and infant feeding behavior. The amount of LNS consumed by subjects
will be monitored weekly, and the reactions to the products will be obtained at the end.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |